Stocktoria
Seres Therapeutics, Inc. MCRB
Seres Therapeutics, Inc. statistics & valuation
Market cap$68.6M
P / E12.0×
P / S86.9×
P / B1.6×
P / FCF79.3×
Net margin721.9%
Return on equity12.9%
FCF margin109.6%
Return on capital-79.1%
Graham number +72.9%$8.16
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($8.16); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -11910.1% | — | — | -2524.0% | -44.5% | -265.3% | -208.3% | -354.8% | -284.7% | -426.5% |
| Net margin | 721.9% | — | — | -3509.5% | -45.2% | -268.3% | -203.7% | -350.0% | -278.4% | -420.7% |
| FCF margin | 109.6% | — | — | -3347.9% | -2.0% | -283.6% | -224.7% | -229.2% | -249.8% | 103.0% |
| Return on assets | 4.1% | 0.1% | -31.7% | -71.7% | -18.5% | -26.0% | -53.1% | -82.1% | -47.2% | -33.6% |
| Return on equity | 12.9% | 1.0% | 253.5% | -2319.9% | -49.9% | -51.0% | 145.4% | 205.9% | -147.3% | -69.0% |
| Debt / equity | — | — | -2.45× | 4.64× | 0.18× | 0.14× | -0.52× | — | — | — |
| Current ratio | 2.56 | 0.94 | 1.78 | 2.28 | 3.69 | 5.79 | 2.18 | 2.20 | 4.90 | 6.51 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.